![]() For example, the Response-Adjusted Therapy for Hodgkin Lymphoma (RATHL) trial, 5 investigating treatment escalation based on early positron emission tomography (PET) response in advanced HL, also included stage IIA with adverse features considered early unfavorable stage for the EORTC. As a consequence, the definition of the unfavorable (U) risk group changes in the different prospective trials, resulting in clinical difficulties when comparing final results. 1 These factors are diversely integrated in the different staging systems developed by the European Organization for Research and Treatment of Cancer (EORTC), 2 the German Hodgkin Study Group (GHSG), 3 and the National Comprehensive Cancer Network (NCCN), 4 leading to different risk categories. In early-stage Hodgkin lymphoma (HL), many factors have been shown to be of prognostic significance notably, bulky disease, number of regions involved, B-symptoms, erythrocyte sedimentation rate (ESR), and advanced age. ![]() TMTV improves baseline risk stratification of patients with early-stage HL compared with current staging systems and the predictive value of early PET response as well. TMTV and iPET2 were independently prognostic and, combined, identified 4 risk groups: low (TMTV≤147+DS1-3 5-year PFS, 95%), low-intermediate (TMTV>147+DS1-3 5-year PFS, 81.6%), high-intermediate (TMTV≤147+DS4-5 5-year PFS, 50%), and high (TMTV>147+DS4-5 5-year PFS, 25%). In multivariable analysis including iPET2, TMTV was the only baseline prognosticator compared with the current staging systems proposed by the European Organization for Research and Treatment of Cancer/Groupe d’Etude des Lymphomes de l’Adulte, German Hodgkin Study Group, or National Comprehensive Cancer Network. TMTV was a prognosticator of PFS ( P 147 cm 3) group (n = 46), respectively, vs 92% and 98% in the low-TMTV group (≤147 cm 3). ![]() The median follow-up was 55 months, with 27 progression-free survival (PFS) and 12 overall survival (OS) events. A total of 258 patients were eligible: 101 favorable and 157 unfavorable. The prognostic value of TMTV was evaluated and compared with baseline characteristics, staging classifications, and iPET2. iPET2 findings were reported negative (DS1-3) or positive (DS4-5) with the Deauville scale (DS). Total metabolic tumor volume (TMTV) was measured on baseline PET. Patients with stage I-II HL enrolled in the standard arm (combined modality treatment) of the H10 trial (NCT00433433) with available baseline PET and interim PET (iPET2) after 2 cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine were included. Merchandise sales – $1.We tested baseline positron emission tomography (PET)/computed tomography (CT) as a measure of total tumor burden to better identify high-risk patients with early-stage Hodgkin lymphoma (HL).Merchandise sales – $1.706 billion Īmblin ( Reliance / Hasbro / Alibaba) (film). ![]() Licensed merchandise – $8.47 billion īandai Namco Holdings ( Super Sentai merchandise).Toho ( Hankyu Hanshin Toho Group) (films) Koyoharu Gotōge and Shueisha (Hitotsubashi Group) (manga) Marvel Entertainment (The Walt Disney Company) Box office & home video – $211 million.Merchandise & licensing – $3.06 billion.Universal Pictures ( The Incredible Hulk) Walt Disney Studios (The Walt Disney Company) Jet aircraft livery sales – $3 million.You can help by adding missing items with reliable sources. This is a dynamic list and may never be able to satisfy particular standards for completeness.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |